- Home
- TTGT vs AUTL Comparison
TTGT vs AUTL Comparison
Compare TTGT & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TTGT | AUTL |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 373.1M | 433.8M |
| IPO Year | 2007 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TTGT | AUTL |
|---|---|---|
| Price | $5.50 | $1.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $11.25 | $8.33 |
| AVG Volume (30 Days) | 317.1K | ★ 2.6M |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $446,514,000.00 | $51,128,000.00 |
| Revenue This Year | $74.33 | $672.42 |
| Revenue Next Year | $3.55 | $84.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 71.55 | ★ 406.67 |
| 52 Week Low | $4.63 | $1.11 |
| 52 Week High | $19.29 | $2.70 |
Technical Indicators
Market Signals| Indicator | TTGT | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 53.69 | 42.42 |
| Support Level | $5.02 | $1.33 |
| Resistance Level | $5.59 | $1.56 |
| Average True Range (ATR) | 0.28 | 0.13 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 55.90 | 16.06 |
Price Performance
Historical ComparisonAbout TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.